Cochrane · systematic review · CD005340
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K, Johnson, N, Lawrie, TA · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
9
No studies
1
Included studies
NR
No studies 1 · 10%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 9 · 90%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of survival outcomes
Population: Women with newly diagnosed epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 0.81 [0.72, 0.9] | 8 studies · 2026 participants | High |
Progression‐free survival | HR 0.78 [0.7, 0.86] | 5 studies · 1311 participants | High |
Summary of severe adverse effects
Population: Women with newly diagnosed epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe adverse effects (G3/4) outcomes | no estimate extracted | NR | No studies |
fever | RR 1.64 [1.13, 2.38] | 5 studies · 1797 participants | High |
fatigue | RR 2.32 [1.06, 5.07] | 3 studies · 1171 participants | High |
gastrointestinal AEs | RR 1.71 [1.28, 2.26] | 5 studies · 1339 participants | High |
infection | RR 3.34 [2.06, 5.43] | 3 studies · 1171 participants | High |
metabolic AEs | RR 4.45 [2.72, 7.26] | 2 studies · 873 participants | High |
pain | RR 7.47 [4.41, 12.67] | 3 studies · 1235 participants | High |
hearing loss | RR 0.67 [0.46, 0.99] | 3 studies · 1009 participants | High |
Summary of survival outcomes
Population: Women with newly diagnosed epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 0.81 [0.72, 0.9] | 8 studies · 2026 participants | High |
Progression‐free survival | HR 0.78 [0.7, 0.86] | 5 studies · 1311 participants | High |
Summary of severe adverse effects
Population: Women with newly diagnosed epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe adverse effects (G3/4) outcomes | no estimate extracted | NR | No studies |
fever | RR 1.64 [1.13, 2.38] | 5 studies · 1797 participants | High |
fatigue | RR 2.32 [1.06, 5.07] | 3 studies · 1171 participants | High |
gastrointestinal AEs | RR 1.71 [1.28, 2.26] | 5 studies · 1339 participants | High |
infection | RR 3.34 [2.06, 5.43] | 3 studies · 1171 participants | High |
metabolic AEs | RR 4.45 [2.72, 7.26] | 2 studies · 873 participants | High |
pain | RR 7.47 [4.41, 12.67] | 3 studies · 1235 participants | High |
hearing loss | RR 0.67 [0.46, 0.99] | 3 studies · 1009 participants | High |